Artivion Reports Third Quarter Revenue of $113.4 Million and Net Income of $6.5 Million

Reuters

Nov 07

<a href="https://laohu8.com/S/AORT">Artivion</a> Reports Third Quarter Revenue of $113.4 Million and Net Income of $6.5 Million

Artivion Inc. reported third quarter 2025 revenue of $113.4 million, up 18% from $95.8 million in the third quarter of 2024. Net income for the quarter was $6.5 million, or $0.13 per fully diluted share, compared to a net loss of $2.3 million, or $0.05 per share, in the same period last year. Non-GAAP net income was $7.9 million, or $0.16 per share, up from $5.0 million, or $0.12 per share, in the third quarter of 2024. Adjusted EBITDA rose 39% to $24.6 million, compared to $17.7 million in the prior year period. The company enrolled its first patient in the ARTIZEN U.S. Investigational Device Exemption trial for Arcevo. Artivion raised its 2025 full year revenue guidance to a range of $439 to $445 million and adjusted EBITDA guidance to $88 to $91 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artivion Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL17872) on November 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581704886"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581704886\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581704886?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581704886","market":"us","top_or_hot":-1,"title":"Artivion Reports Third Quarter Revenue of $113.4 Million and Net Income of $6.5 Million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AORT\">Artivion</a> Reports Third Quarter Revenue of $113.4 Million and Net Income of $6.5 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Artivion Inc. reported third quarter 2025 revenue of $113.4 million, up 18% from $95.8 million in the third quarter of 2024. Net income for the quarter was $6.5 million, or $0.13 per fully diluted share, compared to a net loss of $2.3 million, or $0.05 per share, in the same period last year. Non-GAAP net income was $7.9 million, or $0.16 per share, up from $5.0 million, or $0.12 per share, in the third quarter of 2024. Adjusted EBITDA rose 39% to $24.6 million, compared to $17.7 million in the prior year period. The company enrolled its first patient in the ARTIZEN U.S. Investigational Device Exemption trial for Arcevo. Artivion raised its 2025 full year revenue guidance to a range of $439 to $445 million and adjusted EBITDA guidance to $88 to $91 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artivion Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL17872) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Artivion Reports Third Quarter Revenue of $113.4 Million and Net Income of $6.5 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArtivion Reports Third Quarter Revenue of $113.4 Million and Net Income of $6.5 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 05:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AORT\">Artivion</a> Reports Third Quarter Revenue of $113.4 Million and Net Income of $6.5 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Artivion Inc. reported third quarter 2025 revenue of $113.4 million, up 18% from $95.8 million in the third quarter of 2024. Net income for the quarter was $6.5 million, or $0.13 per fully diluted share, compared to a net loss of $2.3 million, or $0.05 per share, in the same period last year. Non-GAAP net income was $7.9 million, or $0.16 per share, up from $5.0 million, or $0.12 per share, in the third quarter of 2024. Adjusted EBITDA rose 39% to $24.6 million, compared to $17.7 million in the prior year period. The company enrolled its first patient in the ARTIZEN U.S. Investigational Device Exemption trial for Arcevo. Artivion raised its 2025 full year revenue guidance to a range of $439 to $445 million and adjusted EBITDA guidance to $88 to $91 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artivion Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL17872) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B7SZL793.SGD","symbol_name":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL7tJjq7:1","article_id":"2581704886","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581704886","pubTimestamp":1762463646,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Artivion Inc. reported third quarter 2025 revenue of $113.4 million, up 18% from $95.8 million in the third quarter of 2024. Net income for the quarter was $6.5 million, or $0.13 per fully diluted share, compared to a net loss of $2.3 million, or $0.05 per share, in the same period last year. Non-GAAP net income was $7.9 million, or $0.16 per share, up from $5.0 million, or $0.12 per share, in the third quarter of 2024. Adjusted EBITDA rose 39% to $24.6 million, compared to $17.7 million in the prior year period. The company enrolled its first patient in the ARTIZEN U.S. Investigational Device Exemption trial for Arcevo. Artivion raised its 2025 full year revenue guidance to a range of $439 to $445 million and adjusted EBITDA guidance to $88 to $91 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","AORT":"Artivion","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","BK4082":"医疗保健设备","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC"},"translate_title":"Artivion报告第三季度营收1.134亿美元，净利润650万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AORT":0.9},"content_text":"Artivion Reports Third Quarter Revenue of $113.4 Million and Net Income of $6.5 Million\n    \n\n        Artivion Inc. reported third quarter 2025 revenue of $113.4 million, up 18% from $95.8 million in the third quarter of 2024. Net income for the quarter was $6.5 million, or $0.13 per fully diluted share, compared to a net loss of $2.3 million, or $0.05 per share, in the same period last year. Non-GAAP net income was $7.9 million, or $0.16 per share, up from $5.0 million, or $0.12 per share, in the third quarter of 2024. Adjusted EBITDA rose 39% to $24.6 million, compared to $17.7 million in the prior year period. The company enrolled its first patient in the ARTIZEN U.S. Investigational Device Exemption trial for Arcevo. Artivion raised its 2025 full year revenue guidance to a range of $439 to $445 million and adjusted EBITDA guidance to $88 to $91 million.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artivion Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL17872) on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}